According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the use of cryoablation as a treatment for cancers of the lung and kidney will take off at the expense of radiofrequency ablation in the US over the next five years. The US cryoablation device market, consisting of disposable cryoablation devices used in the treatment of kidney, liver, and lung cancer, was valued at approximately $30 million in 2010...
More...
More...